Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814652 | 0.78 | L3MBTL1 (0.57) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL11149733 | 0.77 | L3MBTL1 (0.96) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL20012584 | 0.77 | L3MBTL1 (0.64) | L3MBTL1TSHRHSD11B1KMT2AMEN1 | |
| SCHEMBL4943200 | 0.77 | L3MBTL1 (0.64) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL27326127 | 0.76 | L3MBTL1 (0.68) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL27395104 | 0.76 | L3MBTL1 (0.68) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL27326240 | 0.76 | L3MBTL1 (0.68) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL26848353 | 0.75 | L3MBTL1 (0.62) | L3MBTL1TSHRKMT2AMEN1CYP3A4 | |
| SCHEMBL12794229 | 0.74 | GAA (0.73) | TSHRKMT2AALDH1A1PKM | |
| SCHEMBL13725931 | 0.74 | NPSR1 (0.52) | L3MBTL1TSHRHSD11B1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | L3MBTL1 555/4885TSHR 1817/4885HSD11B1 2021/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | L3MBTL1 555/4885TSHR 1817/4885HSD11B1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.